Business
Medistim is opening a direct sales office in Japan
Medistim is opening a direct sales office in Japan
About this update from Medistim Asa
(Oslo, February 3, 2026) - Medistim ASA (OSE: MEDI), a leading niche providerofultrasound technology headquartered in Oslo, Norway, today announced theestablishment of a direct sales operation in Japan, effective March 16, 2026. Medistim develops and commercializes advanced medical equipment for use incardiac, vascular, and transplant surgery. The expansion into a direct salesmodel in Japan is intended to strengthen the company's market presence andenhance customer engagement in one of its key strategic markets. Thisinitiative underscores Medistim's continued commitment to deliveringhigh-quality service and clinical support to cardiovascular surgeons globallyand aligns with the Company's long-term global growth strategy.Medistim maintains a very strong market position in Japan, where approximately90% of the estimated 17,000 annual coronary artery bypass graft (CABG)procedures are supported by the company's Transit Time Flow Measurement (TTFM)technology.Future growth in the Japanese market is expected to be driven by continuedconversion from installed base systems utilizing TTFM-only functionality tonext-generation platforms integrating both TTFM and High-Frequency Ultrasound(HFUS). This represents a meaningful value-enhancement opportunity within theexisting customer base.In addition, the vascular surgery segment presents significant incrementalgrowth potential, supported by untapped procedural volumes and broaderclinicaladoption of Medistim's technology portfolio."We are pleased to announce this strategic initiative, which will furtherstrengthen our engagement with customers in Japan," said Kari E. Krogstad,President and CEO of Medistim ASA. "The establishment of a direct presence inJapan has been under evaluation for some time, and we have now resolved toproceed. We are well prepared for this transition, with key personnel for thenew subsidiary already in place.Our experience from other markets demonstrates that a direct operating modelenhances customer proximity, supports sustainable revenue growth, andcontributes positively to margins, while ensuring the highest standards ofservice and clinical support. We are confident that this step will reinforceourmarket position and unlock additional growth opportunities in Japan.At the same time, we would like to acknowledge our long-standing distributionpartner, Nippon BXI K.K., for more than three decades of c...